Document Detail

Genetic polymorphism in platelet-derived growth factor and vascular endothelial growth factor are significantly associated with cardiac allograft vasculopathy.
MedLine Citation:
PMID:  16730575     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The role of cytokine gene polymorphism and its association with acute heart allograft rejection and cardiac allograft vasculopathy (CAV) is controversial. The role of growth factor gene polymorphism has never been investigated in heart allograft recipients. METHODS: Seventy heart transplant recipients were studied. Mean age at transplant was 50.4 +/- 12.4 years (73% white, 91% male). Patients were followed for an average of 28 +/- 12 months. Cellular rejection episodes were determined based on criteria established by the International Society of Heart and Lung Transplantation. Angiography and intravascular ultrasound (IVUS) were performed annually. Cytokine and growth factor polymorphism data were analyzed using the single-nucleotide polymorphism polymerase chain reaction (SNP PCR) approach. RESULTS: Patients who developed early CAV, documented by angiography, had increased frequency of the interferon-gamma high-producer phenotype, increased frequency of PDGF-286 AA, and decreased frequency of PDGF-1135 CC (p < 0.03, p < 0.03 and p = 0.01, respectively). Platelet-derived growth factor (PDGF) associations with early CAV were substantiated when vasculopathy was determined by IVUS. Additional associations were identified with vascular endothelial growth factor (VEGF) polymorphisms-1154 GG and -2578 AC (p < 0.03 and p = 0.01, respectively). Some of these associations translated to decreased patient survival, as indicated by Kaplan-Meier analysis. No significant association was identified between cytokine gene polymorphism (tumor necrosis factor-alpha, transforming growth factor-beta, interferon-gamma, interleukin-6 and interleukin-10) and acute cellular rejection episodes. CONCLUSIONS: These data suggest an association between PDGF and VEGF polymorphism and CAV. It is essential, however, due to the redundancy of the immune system and other confounding factors, that future studies be centrally conducted and include multiple programs, large cohorts of patients and properly chosen controls. Only then will we be able to identify the true association between cytokine and growth factor polymorphism and heart transplant outcome.
Anat R Tambur; Salpy Pamboukian; Maria-Rosa Costanzo; Alain Heroux
Related Documents :
1943955 - The "domino-donor" operation in heart and lung transplantation.
3279665 - Late follow-up of children after heart transplantation.
20650355 - Assessment of the potential heart donor: a role for biomarkers?
9436135 - Gingival overgrowth in pediatric heart and heart-lung transplant recipients.
12951315 - Longitudinal bone insufficiency fracture of the tibia in a renal transplant recipient.
23195005 - The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin dur...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation     Volume:  25     ISSN:  1557-3117     ISO Abbreviation:  J. Heart Lung Transplant.     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-05-29     Completed Date:  2006-07-11     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9102703     Medline TA:  J Heart Lung Transplant     Country:  United States    
Other Details:
Languages:  eng     Pagination:  690-8     Citation Subset:  IM    
Division of Organ Transplantation, Department of Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611-3008, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Coronary Angiography
Coronary Disease / genetics*,  immunology,  mortality
Heart Transplantation / immunology*,  mortality
Host vs Graft Reaction
Interferon-gamma / genetics
Interleukin-10 / genetics
Interleukin-6 / genetics
Middle Aged
Platelet-Derived Growth Factor / genetics*
Polymorphism, Single Nucleotide / genetics*
Proto-Oncogene Proteins c-sis / genetics
Transforming Growth Factor beta / genetics
Transplantation, Homologous
Tumor Necrosis Factor-alpha / genetics
Ultrasonography, Interventional
Vascular Endothelial Growth Factor A / genetics*
Reg. No./Substance:
0/Interleukin-6; 0/Platelet-Derived Growth Factor; 0/Proto-Oncogene Proteins c-sis; 0/Transforming Growth Factor beta; 0/Tumor Necrosis Factor-alpha; 0/Vascular Endothelial Growth Factor A; 130068-27-8/Interleukin-10; 82115-62-6/Interferon-gamma
Comment In:
J Heart Lung Transplant. 2007 Jan;26(1):101   [PMID:  17234526 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Carvedilol inhibits platelet-derived growth factor-induced extracellular matrix synthesis by inhibit...
Next Document:  Long-term results of tacrolimus monotherapy in cardiac transplant recipients.